Aggrecan Antikörper

Produktnummer ABIN2664049

Der Maus Monoklonal Anti-Aggrecan-Antikörper wurde für WB, IHC, IP und ICC validiert. Er ist geeignet, Aggrecan in Proben von Human zu detektieren.

Kurzübersicht für Aggrecan Antikörper (ABIN2664049)

Target: Aggrecan (ACAN)

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Aggrecan Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)

Klon: M4004A03

Produktdetails anti-Aggrecan Antikörper

Aufreinigung: The antibody was purified by affinity chromatography.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu Aggrecan

Target: Aggrecan (ACAN)

Andere Bezeichnung: Aggrecan

Hintergrund: Aggrecan, also known as aggrecan 1, is the major proteoglycan in the articular cartilage. This high molecular weight protein exhibits a bottlebrush structure, in which chondroitin sulfate and keratan sulfate chains are attached to an extended protein core. Aggrecan plays an important role in the proper functioning of articular cartilage by providing a hydrated gel structure through its interaction with hyaluronan and link proteins. Aggrecan is expressed by chondrocytes and is found to be crucial in chondroskeletal morphogenesis during development. Mutations in this gene may be involved in skeletal dysplasia and spinal cord degeneration. Structurally, aggrecan is composed of two globular domains (G1 and G2) at the N-terminal end and one globular domain (G3) at the C-terminal end, which are separated by a large extended domain (CS) heavily modified with glycosaminoglycans. G1 and G2 domains of aggrecan are separated by the interglobular domain (IGD). Biologically, the G1 domain interacts with hyaluronan acid and link proteins, which forms stable ternary complexes in the extracellular matrix (ECM). The G2 domain is homologous to the tandem repeats of G1 and link proteins, and is involved in product processing. G3 makes up the carboxyl terminus of the core protein, and enhances glycosaminoglycan modification and product secretion. Also, the G3 domain links the proteoglycan aggregates to the ECM proteins, which are fibulins and tenascins. The degradation of aggrecan appears to initiate at the C-terminus. The population of aggrecan molecules without the G3 domain increases with aging.

Pathways: Glycosaminoglycan Metabolic Process, Dicarboxylic Acid Transport